Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Department of Gynecologic Oncology, St Louis University Hospital, SSM Health, St Louis, Missouri.
JAMA Oncol. 2023 Feb 1;9(2):234-241. doi: 10.1001/jamaoncol.2022.6278.
Changes in postsurgical opioid prescribing practices may help reduce chronic opioid use in surgical patients.
To investigate whether postsurgical acute pain across different surgical subspecialties can be managed effectively after hospital discharge with an opioid supply of 3 or fewer days and whether this reduction in prescribed opioids is associated with reduced new, persistent opioid use.
DESIGN, SETTING, AND PARTICIPANTS: In this prospective cohort study with a case-control design, a restrictive opioid prescription protocol (ROPP) specifying an opioid supply of 3 or fewer days after discharge from surgery along with standardized patient education was implemented across all surgical services at a tertiary-care comprehensive cancer center. Participants were all patients who underwent surgery from August 1, 2018, to July 31, 2019.
Main outcomes were the rate of compliance with the ROPP in each surgical service, the mean number of prescription days and refill requests, type of opioid prescribed, and rate of conversion to chronic opioid use determined via a state-run opioid prescription program. Postsurgical complications were also measured.
A total of 4068 patients (mean [SD] age, 61.0 [13.8] years; 2528 women [62.1%]) were included, with 2017 in the pre-ROPP group (August 1, 2018, to January 31, 2019) and 2051 in the post-ROPP group (February 1, 2019, to July 31, 2019). The rate of compliance with the protocol was 95%. After implementation of the ROPP, mean opioid prescription days decreased from a mean (SD) of 3.9 (4.5) days in the pre-ROPP group to 1.9 (3.6) days in the post-ROPP group (P < .001). The ROPP implementation led to a 45% decrease in prescribed opioids after surgery (mean [SD], 157.22 [338.06] mean morphine milligram equivalents [MME] before ROPP vs 83.54 [395.70] MME after ROPP; P < .001). Patients in the post-ROPP cohort requested fewer refills (367 of 2051 [17.9%] vs 422 of 2017 [20.9%] in the pre-ROPP cohort; P = .02). There was no statistically significant difference in surgical complications. The conversion rate to chronic opioid use decreased following ROPP implementation among both opioid-naive patients with cancer (11.3% [143 of 1267] to 4.5% [118 of 2645]; P < .001) and those without cancer (6.1% [19 of 310] to 2.7% [16 of 600]; P = .02).
In this cohort study, prescribing an opioid supply of 3 or fewer days to surgical patients after hospital discharge was feasible for most patients, led to a significant decrease in the number of opioids prescribed after surgery, and was associated with a significantly decreased conversion to long-term opioid use without concomitant increases in refill requests or significant compromises in surgical recovery.
重要性:手术后阿片类药物处方规定的改变可能有助于减少手术患者的慢性阿片类药物使用。
目的:调查不同外科亚专科的手术后急性疼痛在出院后是否可以通过 3 天或更短的阿片类药物供应有效管理,以及这种减少开具的阿片类药物是否与减少新的、持续的阿片类药物使用有关。
设计、地点和参与者:在这项具有病例对照设计的前瞻性队列研究中,在一家三级综合癌症中心的所有外科服务中实施了一项限制阿片类药物处方的方案(ROPP),规定出院后阿片类药物供应为 3 天或更短,并进行标准化的患者教育。参与者均为 2018 年 8 月 1 日至 2019 年 7 月 31 日接受手术的患者。
主要结果和测量:主要结果是每个外科服务中遵守 ROPP 的比率、处方天数和续药请求的平均数量、开具的阿片类药物类型以及通过州立阿片类药物处方计划确定的慢性阿片类药物使用的转换率。还测量了手术后并发症。
结果:共纳入 4068 例患者(平均[SD]年龄 61.0[13.8]岁;2528 例女性[62.1%]),其中 2017 例在 ROPP 前组(2018 年 8 月 1 日至 2019 年 1 月 31 日),2051 例在 ROPP 后组(2019 年 2 月 1 日至 2019 年 7 月 31 日)。方案的遵守率为 95%。ROPP 实施后,阿片类药物处方天数从 ROPP 前组的平均(SD)3.9(4.5)天减少到 ROPP 后组的 1.9(3.6)天(P<.001)。ROPP 的实施使手术后开具的阿片类药物减少了 45%(平均[SD],ROPP 前为 157.22[338.06]吗啡毫克当量[MME],ROPP 后为 83.54[395.70]MME;P<.001)。ROPP 后组的患者要求续药的次数更少(2051 例中的 367 例[17.9%]与 2017 例中的 422 例[20.9%]在前 ROPP 组;P=.02)。手术并发症无统计学显著差异。ROPP 实施后,癌症患者(阿片类药物无使用史者:11.3%[143 例/1267 例]至 4.5%[118 例/2645 例];P<.001)和无癌症患者(6.1%[19 例/310 例]至 2.7%[16 例/600 例];P=.02)的慢性阿片类药物使用转化率降低。
结论和相关性:在这项队列研究中,大多数患者出院后给予 3 天或更短的阿片类药物供应是可行的,这显著减少了手术后开具的阿片类药物数量,并与长期阿片类药物使用的转化率显著降低相关,而没有同时增加续药请求或对手术恢复造成显著影响。